Comparative Pharmacology
Head-to-head clinical analysis: ISOPAQUE 280 versus ISOPAQUE 440.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOPAQUE 280 versus ISOPAQUE 440.
ISOPAQUE 280 vs ISOPAQUE 440
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isopaque 280 (metrizoate) is an ionic, high-osmolar iodinated radiocontrast agent that attenuates X-rays by increasing the density of tissues where it distributes, thereby enhancing vascular and organ visualization during imaging.
Iodinated radiocontrast agent that attenuates X-rays by increasing the iodine content in tissues, providing enhanced visualization of vasculature and organs during imaging procedures.
Iohexol (ISOPAQUE 280) is administered intravenously, intra-arterially, or by other appropriate routes. Typical adult dose for CT imaging: 50–150 mL (concentration 280 mg I/mL) as a bolus or infusion. For angiography: 5–80 mL per injection, depending on procedure. Repeat doses may be given up to a total of 350 mL.
Intravenous: 50-100 mL (22.05-44.1 g iodine) as a single dose for CT imaging; intra-arterial: 5-80 mL (2.2-35.28 g iodine) depending on procedure; dose is based on imaging requirements and patient weight.
None Documented
None Documented
Terminal elimination half-life is 1.5–2 hours in patients with normal renal function; prolonged to >10 hours in severe renal impairment, requiring dose adjustment.
Terminal elimination half-life is approximately 1.5 to 2 hours in patients with normal renal function. May be prolonged in renal impairment, correlating with creatinine clearance; dose adjustment not typically required for diagnostic procedures.
Renal: approximately 95% of the dose is excreted unchanged in the urine within 24 hours via glomerular filtration. Fecal: <5%; biliary excretion is negligible.
Primarily renal excretion via glomerular filtration. Approximately 95% of the administered dose is excreted unchanged in the urine within 24 hours. Less than 5% is eliminated via biliary/fecal routes.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent